Aarti Drugs Limited (AARTIDRUGS.NS) NSE

422.00

+9.65(+2.34%)

Updated at December 24 03:30PM

Currency In INR

Aarti Drugs Limited

Address

Mahendra Industrial Estate

Mumbai, 400022

India

Phone

91 22 2401 9025

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1064

First IPO Date

September 19, 2003

Key Executives

NameTitlePayYear Born
Prakash Moreshwar PatilChairman, MD & CEO29.39M1947
Harit Pragji ShahWhole-Time Director26.87M1963
Uday Moreshwar PatilWhole-Time Director26.87M1963
Harshit Manila SavlaJoint MD & Executive Director26.87M1962
Rashesh Chandrakant GogriMD & Executive Director26.87M1974
Adhish Prakash PatilChief Financial Officer & Chief Operating Officer01983
Dhanaji L. KakadeVice President of Technical0N/A
Rushikesh DeoleCompany Secretary & Compliance Officer0N/A
Vishwa Harshit SavlaManaging Director of the Pinnacle Life Science Private Limited0N/A

Description

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.